European Archives - Page 507 of 1056 - European Medical Journal

Managing Chronic Pain in Osteoarthritis and Rheumatoid Arthritis

ON DAY 3 of the European Alliance of Associations for Rheumatology (EULAR) 2021 Congress, participants from across the globe accessed the virtual platform to join Jon Lampa, Associate Professor, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, and his panel as they explored the challenges and opportunities of managing chronic pain in osteoarthritis and rheumatoid arthritis.

Mind the Gap: Balancing Remission and Risk of Relapse in ANCA-Associated Vasculitis

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an umbrella term for a group of rare, multisystem autoimmune…

Rheumatology Feature Image

Association Between Environmental Air Pollution and Rheumatoid Arthritis Flares

Environmental air pollution has been linked to the pathogenesis of rheumatoid arthritis (RA).1 Nevertheless, there is no evidence linking higher concentrations of air pollutants with the risk of RA reactivations.

Striking the Right Balance in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis

AAV are a type of small-vessel necrotising vasculitis that manifest as systemic diseases, with pulmonary; ear, nose, and throat; and renal involvement. The key pathological feature of AAV is the presence of ANCA, which can target two neutrophil antigens, myeloperoxidase (MPO) and proteinase 3 (PR3).

Rheumatology Feature Image

Efficacy and Safety of TNF-α Antagonists and Tocilizumab in Takayasu Arteritis: Multi-centre, Retrospective Study of 209 Patients

Takayasu arteritis (TA) is a chronic inflammatory large-vessel vasculitis, predominantly affecting the aorta and its main branches.

EULAR Interview: Joan Bathon

Joan Bathon | Member of the EULAR Scientiﬁc Programme Committee; Director of the Division of Rheumatology at New York-Presbyterian Hospital…

Interview: Christopher Edwards

Christopher Edwards | Professor and Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology; Musculoskeletal Research Unit…

Rheumatology Feature Image

RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis

EULAR Interview: Ricardo Ferreira

Ricardo Ferreira | Chair of the EULAR Committee of Health Professionals in Rheumatology; Clinical Research Nurse and Study Coordinator…

Interview: Karen Walker-Bone

Karen Walker-Bone | Professor and Honorary Consultant in Occupational Rheumatology, University of Southampton; Director, Arthritis Research…